The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1203
February 28, 2005
View Complete Issue         Table of Contents 2019 
Two Once-Daily Fixed-Dose NRTI Combinations for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Once-Daily Fixed-Dose NRTI Combinations for HIV
February 28, 2005 (Issue: 1203)
The FDA has approved emtricitabine/tenofovir (Truvada - Gilead) and abacavir/lamivudine (Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for once-daily use in treatment of HIV...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Once-Daily Fixed-Dose NRTI Combinations for HIV
Article code: 1203b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.